Rizatriptan Benzoate Tablet
Product Images NDC 71335-1149

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-1149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351149)

This is a medication description for Rizatriptan tablet, which is pink and round in shape, containing Benzoate 5mg. The tablet should be stored at room temperature, and it is available in a blister pack of Maxalt Sm%. The medication is manufactured by Rising Health LLC and comes in a package of 30 tablets. The NDC code for this tablet is 7133511491 06613301523487.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

The given text shows a graph representing the probability of achieving an initial headache response after treatment with placebo or two doses of Rizatriptan Benzoate (5mg, 10mg) within the first two hours. The data is based on pooled results from four outpatient trials (Studies 1, 2, 3, and 4) and displays the Kaplan-Meier plot. Patients who did not achieve headache response within two hours or took additional treatment were censored at 2 hours.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

This figure shows the estimated probability of patients taking a second dose of either Rizatriptan Benzoate tablets or other medication for migraines over 24 hours following the initial dose of study treatment. The table includes the percentage of patients taking either Rizatriptan Benzoate 5 mg or 10 mg at different times post-dose. This data is based on 4 placebo-controlled outpatient clinical trials and includes patients who had a headache response at 2 hours and those who had no response to the initial dose. Patients not using additional treatments were censored at 24 hours. Remedication was not allowed within 2 hours post-dose.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.